The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Party season approaches; but first, conferences.

Syndax scored the first menin approval, but Kura is first with a licensing deal.